Article Text

other Versions

Download PDFPDF
The use of infliximab in ocular inflammation
  1. Catherine A.M. Prendivillle (camprendiville{at},
  2. Maeve O'Doherty (maeveodoherty{at},
  3. Paul Moriarty (moripds{at},
  4. Lorraine Cassidy (dalye1{at}
  1. Royal Victoria Eye and Ear Hospital, Eire
  2. Royal Victoria Eye and Ear Hospital, Eire
  3. Royal Victoria Eye and Ear Hospital, Eire
  4. Royal Victoria Eye and Ear Hospital, Eire


    Introduction: Experience with anti TNF αmedications in ophthalmology has been mainly in the treatment of resistant uveitis and scleritis. There have been a few case reports1 and one case series13 detailing the use of Infliximab in the treatment of orbital inflammatory disease. However there is still limited experience with these agents in a variety of orbital inflammatory conditions. We describe successful suppression of inflammation with Infliximab in the Idiopathic orbital inflammation, thyroid associated orbital inflammation and chronic relapsing inflammatory optic neuropathy.

    Methods: This is a retrospective observational case series of five cases of orbital and ocular inflammation.

    Results: We describe effects of Infliximab in the treatment of 3 cases of orbital inflammation and 2 cases of CRION all of which were unresponsive to alternative immune modulators. The patients received relief of symptoms and signs of inflammation in all 5 cases. However, this relief was not absolute as symptoms returned around week 5 post inflammation.

    Conclusion: This report highlights the expanding role of the biological agents in ophthalmology. Although, not the answer in treatment, they offer a valuable alternative to steroids in cases of refractory inflammation.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.